The study compared two strategies after initial therapy: continuing lenalidomide maintenance beyond a two-year mark versus stopping treatment at two years. Researchers reported no overall survival advantage for the longer-duration approach, suggesting that, for the trial’s specific patient population, indefinite therapy may not translate into better long-term outcomes.

In multiple myeloma, maintenance treatment aims to suppress residual disease and delay relapse. However, as therapeutic regimens have improved over the past two decades, some patients now achieve sustained control for extended periods. This changing landscape increases the importance of determining not only whether a therapy works, but also how long it should be used to maximize benefit while limiting harm.

Mayo Clinic hematologist Shaji Kumar, M.D., emphasized that “longer” is not automatically “better,” particularly when treatment options become more effective. He noted that clinical decision-making should increasingly incorporate duration—an often overlooked variable that can influence quality of life, toxicity exposure, and health care costs.

Another trial leader, S. Vincent Rajkumar, M.D., highlighted the potential patient impact. If maintenance therapy can be safely discontinued after a defined interval, clinicians may reduce treatment burden and support shared decision-making based on evidence rather than convention.

The research applies specifically to patients with standard-risk multiple myeloma who did not receive an upfront stem cell transplant. That detail matters because disease biology and treatment intensity differ across risk categories and treatment pathways, potentially changing the balance between benefit and ongoing therapy.

The trial was supported through the ECOG-ACRIN Cancer Research Group and involved backing from the U.S. National Institutes of Health’s National Cancer Institute via the National Clinical Trials Network. Additional support came from Amgen, reflecting the collaborative, large-scale nature of the investigation.

Researchers say additional studies are underway to refine maintenance duration for high-risk disease and to test whether measurable residual disease (MRD) measurements could enable more individualized treatment stopping points.

The publication, featured in The New England Journal of Medicine, underscores a broader principle for oncology trials: adding new therapies remains crucial, but trials should also clarify when treatment can be responsibly paused or ended.

Subject of Research: Lenalidomide maintenance therapy duration in standard-risk multiple myeloma
Article Title: Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
News Publication Date: 15-Jul-2026
Web References: https://www.nejm.org/doi/full/10.1056/NEJMoa2600157
References: Mayo Clinic News Network and ECOG-ACRIN Cancer Research Group trial description (as provided in the source text)
Image Credits: Not provided
Keywords: multiple myeloma, lenalidomide, maintenance therapy, clinical trial, standard-risk, overall survival, measurable residual disease (MRD), ECOG-ACRIN

The significance of understanding PNIF cannot be overstated. Peak nasal inspiratory flow represents a critical measure of nasal patency and function, providing insights into how well a patient can breathe through their nose. This measure serves as a crucial objective assessment that complements subjective assessments of nasal obstruction, which are often influenced by various psychological and environmental factors. Understanding PNIF in the context of CRSwNP not only furthers our comprehension of respiratory health challenges but also aids in tailoring treatment approaches.

CRSwNP is a debilitating condition afflicting a considerable number of individuals, significantly impacting their quality of life and daily functioning. Symptoms often include chronic nasal obstruction, loss of smell, and recurrent sinus infections, contributing to a burden that affects both physical and mental health. The hormonal and inflammatory pathways involved in CRSwNP illustrate complex biological interactions, indicating the necessity for comprehensive research into these processes and their ramifications on patients’ respiratory efforts.

The most recent correction to the article by Desrosiers and colleagues emphasizes the importance of analyzing the data from both the SINUS-24 and SINUS-52 studies. These trials explored various treatment regimens, focusing on understanding how medical and surgical interventions could affect patient outcomes in terms of both subjective and objective measures of nasal obstruction. It is crucial to note that while these studies represent a large patient cohort, the nuances between individual responses to treatment still warrant discussion, indicating the heterogeneous nature of CRSwNP.

Moreover, the study underscores the utility of PNIF in routine clinical practice. Evaluating PNIF offers an actionable measure that can inform healthcare providers about the severity of nasal obstruction and potentially guide treatment decisions. The relationship between nasal airflow and the perception of obstruction also sheds light on the psychological dimensions of nasal conditions. Patients with CRSwNP often report a higher degree of discomfort despite variable nasal airflow measurements. This disconnect emphasizes the complexity of managing such conditions and highlights the necessity for holistic approaches to patient care.

Additionally, the importance of the correction made to the original article cannot be undervalued. In scientific writing, accuracy is paramount, as it ensures that subsequent research builds on validated information. The correction was significant as it aims to refine the interpretation of results, allowing better clarity for both researchers and clinicians alike. Such adjustments can shape future guidelines for the management of CRSwNP, thereby driving forward advancements in therapeutic strategies.

The researchers involved in this study acknowledge the potential for a paradigm shift in how nasal obstruction is assessed and treated. Historically, the focus has predominantly been on imaging diagnostics and subjective symptom questionnaires. However, the emerging significance of objective measures like PNIF introduces a new dimension to the evaluation process. Armed with more precise tools, clinicians can more effectively monitor treatment efficacy over time, enhancing personalized medicine approaches in otorhinolaryngology.

As investigations continue to explore the interplay between nasal function and the various treatment modalities available for CRSwNP, researchers are also examining the underlying pathophysiology of the disease. Insights derived from understanding nasal aerodynamics provide valuable context for how inflammation, whether allergic or non-allergic, impacts airflow and patient experiences overall. This research could lead to breakthroughs in devising targeted therapies that address both the obstruction of nasal passages and the inflammatory responses contributing to CRSwNP.

The ramifications of such findings extend far beyond academic circles. For patients enduring the chronic nature of CRSwNP, the implications of a better understanding of PNIF and its relationship to nasal obstruction resonate deeply. The hope for improved treatment strategies that enhance quality of life is a shared goal between researchers and those affected by the condition. As such, the importance of continuing to refine our clinical approaches through research cannot be overstated.

Moreover, with the advent of newer therapeutic options, including biologic agents specifically designed to target inflammatory pathways in CRSwNP, the integration of PNIF assessments into routine practice may facilitate quicker adjustments to treatment plans. Not only does this enhance patient outcomes, but it also fosters a more dynamic interaction between patients and healthcare providers, wherein both parties can engage actively in the management of care.

Going forward, the lessons gleaned from the SINUS-24/-52 studies will undoubtedly serve as a foundation for future research endeavors. The exploration of nasal airflow and obstruction will likely continue to be a compelling area of study, prompting new questions that could redefine clinical practices in the field of otorhinolaryngology.

In conclusion, the recent clarification provided by Desrosiers et al. heralds not only a step forward in understanding CRSwNP and nasal function but also sets the stage for ongoing discourse that is essential for advancing patient-centered care. As researchers delve deeper into the complexities of nasal obstruction, the evolution of assessment methodologies, including the role of PNIF, will be crucial in shaping effective treatments and improving health outcomes for patients grappling with the challenges posed by this prevalent condition.

The journey toward better management of CRSwNP is a collaborative effort involving patients, researchers, and clinicians alike. Each new finding contributes to a more comprehensive tapestry of knowledge, ultimately empowering individuals to take charge of their health in the face of chronic illness. The potential for innovative, effective treatments fueled by ongoing research is bright, illuminating the path towards healthier futures for those affected by severe nasal obstruction.

Subject of Research: Relationship between peak nasal inspiratory flow (PNIF) and nasal obstruction in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP).

Article Title: Correction to: Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies.

Article References:

Desrosiers, M., Nash, S., Lane, A. et al. Correction to: Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 Studies. Adv Ther (2025). https://doi.org/10.1007/s12325-025-03444-9

Image Credits: AI Generated

DOI:

Keywords: CRSwNP, PNIF, nasal obstruction, SINUS-24, SINUS-52 studies.

Adalimumab, marketed under the name Humira, has been used extensively for conditions like rheumatoid arthritis, Crohn’s disease, and psoriasis, among others. However, recent investigations underscore a nuanced aspect of adalimumab therapy—the concept of immunogenicity. Immunogenicity refers to the ability of a substance, such as a drug, to provoke an immune response. In the context of adalimumab, certain patients develop anti-drug antibodies that can significantly reduce the drug’s efficacy and potentially lead to adverse reactions. This phenomenon raises important questions about the long-term management and effectiveness of adalimumab in patients with noninfectious uveitis.

The study conducted by Han et al. emphasizes the importance of TDM in managing therapeutic regimens for patients suffering from noninfectious uveitis. Therapeutic drug monitoring allows healthcare providers to evaluate drug levels in the bloodstream and make informed decisions regarding dosage adjustments. This is particularly pivotal in conditions where maintaining adequate drug levels is essential for disease control. The research illustrates that subtherapeutic levels often correlate with poor patient outcomes, while therapeutic levels can provide significant relief from symptoms and disease progression.

Noninfectious uveitis, often characterized by inflammation of the uvea, can lead to severe complications, including vision loss. The immunological component of this condition is complex, as it involves a delicate balance between the body’s immune response and the potential for self-damage. Adalimumab is designed to target and inhibit tumor necrosis factor-alpha (TNF-α), a key cytokine involved in the inflammatory process, thus playing a vital role in the management of uveitis. The study’s focus on the immunogenicity of adalimumab further complicates this picture, as the emergence of antibodies against the drug can lead to inadequate therapy and exacerbation of symptoms.

The findings of the study are crucial, especially given the growing incidence of noninfectious uveitis and its debilitating effects. By employing TDM, healthcare professionals can tailor treatment strategies that account for individual variations in drug metabolism and immune response. The study conducted by Han et al. presents compelling evidence that supports the argument for adopting routine TDM in clinical practice to enhance the management of patients receiving adalimumab.

Moreover, the nuances of immunogenicity in adalimumab therapy extend beyond mere semantics. They indicate a shift toward safer, more effective personalized medicine. This approach considers the unique immune profiles of patients and potentially addresses the root causes of treatment failures. Evaluating the immunogenic potential of biological medications is crucial for ensuring that patients derive maximum benefit from these therapies while minimizing risks.

As clinical practices evolve, the integration of immunogenicity studies into routine assessments can transform the standard of care for patients suffering from chronic autoimmune conditions. This could lead to the development of predictive markers that can help anticipate which patients are at risk of developing anti-drug antibodies. Such advancements will not only foster better management of medications but could also potentially lead to breakthroughs in drug formulation.

Examining the intersection of immunogenicity and therapeutic drug monitoring opens a new dialogue within the regulatory frameworks that govern drug approvals. Pharmaceutical companies are now challenged to include thorough immunogenicity assessments in their development pipelines. This comprehensive approach not only addresses safety concerns but also enhances the therapeutic landscape for patients worldwide.

It is also essential to recognize that the journey of implementing routine TDM and addressing immunogenicity is fraught with challenges. Health care providers face practical hurdles, including the availability of resources for frequent monitoring and the need for robust protocols to interpret the data obtained. However, the long-term benefits in terms of patient outcomes and reduced healthcare costs present a compelling case for overcoming these obstacles.

As the landscape of autoimmune disease treatment evolves, studies like that of Han et al. herald promising advancements in our understanding of drug therapy and immunogenicity. The intersection of TDM and immunogenicity underscores the critical need for ongoing research and investment in patient-centered strategies that enhance therapeutic efficacy. Focused efforts in this area could pave the way for more personalized approaches to treating complex medical conditions.

In conclusion, the findings of Han et al. serve as a pivotal reminder of the importance of continued exploration and innovation in the field of immunology. By harnessing the power of therapeutic drug monitoring and deepening our understanding of immunogenicity, we can make strides toward improving patient care in noninfectious uveitis and beyond. The future is bright, and continued research endeavors will undoubtedly shape the landscape of autoimmune disease management for years to come.

Subject of Research: Immunogenicity of Adalimumab in Patients with Noninfectious Uveitis based on Therapeutic Drug Monitoring

Article Title: Immunogenicity of adalimumab in patients with noninfectious uveitis based on therapeutic drug monitoring.

Article References: Han, JW., Zhou, Y., Guo, J. et al. Immunogenicity of adalimumab in patients with noninfectious uveitis based on therapeutic drug monitoring. J Transl Med 23, 1232 (2025). https://doi.org/10.1186/s12967-025-07352-y

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07352-y

Keywords: Immunogenicity, therapeutic drug monitoring, adalimumab, noninfectious uveitis, personalized medicine.

This exploratory, randomized pilot study, conducted across multiple centers, sought to assess the safety and immunomodulatory effects of BJIKT—a well-known herbal remedy used traditionally in East Asian medicine for its anti-inflammatory and fatigue-relieving properties. The study specifically targeted patients with advanced NSCLC receiving atezolizumab monotherapy, an anti-PD-L1 checkpoint inhibitor widely used in clinical oncology. By integrating this herbal medicine with modern immunotherapy, the researchers aimed to explore if BJIKT could mitigate some common treatment-related adverse events such as fatigue and muscle wasting, while potentially enhancing immune activation.

The trial enrolled 28 patients who were randomly assigned to receive either BJIKT or a placebo, with both groups continuing standard atezolizumab therapy. Throughout the study, the team meticulously monitored adverse events (AEs), immune-related adverse events (irAEs), fatigue levels, and the progression of muscle loss, aiming to uncover interactions between the herbal treatment and immune checkpoint blockade. Beyond clinical symptomatology, a subset of patients underwent detailed immune profiling to shed light on the cellular immune mechanisms potentially influenced by BJIKT.

Findings revealed that adverse events were prevalent in over half of participants, a not unexpected outcome given the aggressive nature of cancer immunotherapy. Intriguingly, the BJIKT group exhibited a higher incidence of AEs (64.29%) compared to the placebo group (42.86%), though the majority of these events were mild to moderate and resolved by the conclusion of the trial. This raises important safety considerations but also underscores the complex interplay between herbal compounds and immune modulation therapies, warranting further pharmacovigilance in larger cohorts.

From an efficacy standpoint, the objective response rate (ORR) and disease control rate (DCR) were numerically higher in the BJIKT-treated group—16.67% versus 8.33% for ORR and 41.67% versus 25% for DCR compared to placebo—though these differences did not reach statistical significance. These encouraging trends suggest that BJIKT might augment tumor growth control during ICI therapy, possibly by enhancing the host immune system’s anti-tumor prowess. Nonetheless, the lack of statistical significance tempers overenthusiasm and highlights the exploratory nature of this pilot trial.

One of the more compelling aspects of the study lies in its immunological analyses. The researchers detected a significant reduction in PD-1 positive CD8+ T cells in patients receiving BJIKT, implying a decrease in T cell exhaustion—a state where T cells become less functional due to chronic antigen exposure, commonly seen in cancer. This finding indicates that BJIKT may reinvigorate cytotoxic T cells, a pivotal cell population responsible for directly attacking tumor cells. Conversely, while PD-1+ CD4+ T cell numbers also declined with BJIKT, this change was not statistically significant, suggesting a selective modulation of T cell subsets.

Beyond T cells, a notable increase in natural killer (NK) cell counts was observed in the BJIKT group. NK cells constitute an essential arm of innate immunity, capable of recognizing and destroying cancer cells without prior sensitization. The elevation of these effector cells may reflect enhanced innate immune surveillance facilitated by BJIKT, potentially contributing to improved tumor control in NSCLC. Moreover, immune profiling revealed trends toward increased activation of CD4+ T cells and the overall proportion of CD3+CD4+ cells, indicating a broader stimulation of helper T cell-mediated immune orchestration during treatment.

BJIKT’s capacity to alleviate fatigue and muscle loss—common debilitating symptoms experienced by patients undergoing immunotherapy—was also examined. While the herbal treatment showed a trend toward mitigating these symptoms, the changes were not statistically significant. Still, these observations correlate with BJIKT’s traditional use in managing fatigue and chronic inflammation, suggesting it may hold supportive care value for NSCLC patients in future integrative oncology frameworks.

The study’s design as a randomized, placebo-controlled pilot trial provides valuable preliminary insights but naturally comes with limitations inherent to small sample sizes, which restrict the statistical power to detect definitive effects. However, the findings lay a foundation for subsequent larger-scale investigations to validate BJIKT’s immunomodulatory benefits and safety profile in combination with ICIs. Such follow-up trials could also dissect the molecular pathways involved, potentially revealing novel complementary mechanisms by which traditional herbal medicine synergizes with cutting-edge immunotherapies.

Notably, the interplay between BJIKT and the complex tumor-immune microenvironment highlights the exciting potential of combining phytochemicals with immuno-oncological agents. This fusion of ancient herbal wisdom with modern molecular oncology could pave the way for innovative, multi-modal cancer treatment regimens aimed at boosting efficacy while minimizing toxicities. Furthermore, the selective immune effects observed with BJIKT—specifically the reduction of immune exhaustion markers and augmentation of NK cells—underscore the importance of immune homeostasis in achieving sustained anti-tumor responses.

From a clinical perspective, this research advocates for integrating complementary therapies like BJIKT into the multidisciplinary care of NSCLC patients receiving ICIs. Positive modulation of immune function and alleviation of adverse symptom burden could improve patient adherence to therapy and quality of life. However, the necessity for rigorous validation studies, standardized herbal preparations, and mechanistic elucidations cannot be overstated before broad application.

Additionally, the trial was registered with the Clinical Research Information Service of Korea, ensuring adherence to ethical and methodological standards. Such transparency not only bolsters credibility but also facilitates collaboration, data sharing, and global efforts to refine cancer therapies. Future studies may build upon this pilot trial to design adaptive, biomarker-driven approaches targeting immune exhaustion and enhancing effector cell function in NSCLC and beyond.

In summary, this pioneering research sheds light on the prospective role of Bojungikki-Tang as an adjunctive agent capable of finely tuning the immune landscape in NSCLC patients undergoing atezolizumab therapy. While conclusive evidence remains forthcoming, the reported reductions in immune exhaustion markers and elevations in innate immune effectors inspire optimism for harnessing herbal pharmacology in the fight against lung cancer. This convergence of traditional medicine and immuno-oncology represents a fertile frontier warranting enthusiastic scientific pursuit.

As the oncology community continues to grapple with the challenges of maximizing immunotherapy benefit, findings like these energize the search for integrative strategies. Bojungikki-Tang’s ancient formula, reinterpreted through the lens of modern immune profiling, exemplifies how history may inform future breakthroughs. Clinical trials with larger cohorts, longer follow-up, and multi-omics analyses will be imperative to validate these preliminary signals and ultimately translate them into robust, patient-centered cancer care innovations.

Subject of Research: Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors

Article Title: Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study

Article References:
Ko, M.M., Na, S.W., Yi, J.M. et al. Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study. BMC Cancer 25, 1229 (2025). https://doi.org/10.1186/s12885-025-14629-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14629-4